Darwin Biosciences Overview

  • Status
  • Private
  • Latest Deal Type
  • Grant
  • Latest Deal Amount
  • $139K
Latest Deal Amount
  • Investors
  • 3

Darwin Biosciences General Information

Description

Manufacturer of saliva-based diagnostic equipment intended to identify asymptomatic or pre-symptomatic infectious disease. The company's equipment is expected to be hand-held and self-administered, so that people can monitor their own health at home, enabling users to monitor their health on a regular basis at an affordable cost.

Contact Information

Website
Ownership Status
Privately Held (backing)
Financing Status
Accelerator/Incubator Backed
Primary Industry
Diagnostic Equipment
Other Industries
Monitoring Equipment
Biotechnology
Primary Office
  • 370 Jade Street
  • Broomfield, CO 80020
  • United States

Darwin Biosciences Timeline

2017201820192020
Financing Round
Want detailed data on 2M+ companies?

What you see here scratches the surface

Request a free trial
Want to dig into this profile?

We’ll help you find what you need

Learn more

Darwin Biosciences Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Grant 13-Apr-2020 $139K 0000 Completed Startup
1. Accelerator/Incubator 08-Apr-2020 0000 0000 Completed Startup
To view Darwin Biosciences’s complete valuation and funding history, request access »

Darwin Biosciences Executive Team (5)

Name Title Board Seat Contact Info
Nicholas Meyerson Ph.D Co-Founder and Chief Executive Officer
Richard Whitcomb Chief Operating Officer
Camille Paige Co-Founder
Qing Yang Ph.D Co-Founder
Sara Sawyer Ph.D Co-Founder
To view Darwin Biosciences’s complete executive team members history, request access »

Darwin Biosciences Investors (3)

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info
Monfort School of Business Entrepreneurial Challenge Other 000 0000 000000 0
Venture Partners at CU Boulder Corporation 000 0000 000000 0
Catalyze CU Accelerator/Incubator Minority 000 0000 000000 0
To view Darwin Biosciences’s complete investors history, request access »